Clinical Trial: BR101 in Patients With Relapsed/Refractory Multiple Myeloma

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07537049) titled 'BR101 in Patients With Relapsed/Refractory Multiple Myeloma' on April 12.

Brief Summary: This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the maximum tolerated dose, safety, pharmacokinetic profile following administration of BR101 injection, and preliminary efficacy in subjects with relapsed or refractory multiple myeloma.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM)

Intervention: BIOLOGICAL: BR101 injection

Single doses and Multiple doses of BR101 injection will be infused.

Recruitment Status: NOT_YET_RECRUITING

Spons...